A rteriosclerosis is an inflammatory vascular disease that is caused by a series of processes, including endothelial activation, the migration of macrophages and other inflammatory cells, and proliferative responses of vascular smooth muscle cells. 1 Recent studies in vitro have suggested that the small GTP-binding protein Rho and its target protein Rho-kinase/ ROK/ROCK [2] [3] [4] play an important role in various cellular functions, including smooth muscle contraction, 5, 6 actin cytoskeleton organization, 7, 8 cell adhesion and motility, 9 cytokinesis, 10 and gene expression, 11 all of which may be involved in the pathogenesis of arteriosclerosis. We have recently demonstrated that Rho-kinase is functionally upregulated at the inflammatory coronary lesions and plays an important role in the pathogenesis of coronary hyperconstriction in our porcine model with interleukin (IL)-1␤. 12 The IL-1␤-treated coronary segment is characterized by luminal reduction caused by neointimal formation and constrictive remodeling. 13 Thus, our porcine model may be useful in the examination of the molecular mechanism of coronary arteriosclerosis in humans.
We have recently found that hydroxyfasudil, an active metabolite of fasudil after oral absorption, is a potent and specific inhibitor of Rho-kinase and markedly inhibits coronary hyperconstriction and macrophage migration. 14, 15 Thus, it is conceivable that Rho-kinase is involved not only in the pathogenesis of coronary artery spasm but also in that of coronary arteriosclerosis.
To test this hypothesis, we examined in the present study whether selective inhibition of Rho-kinase by the local adenovirus-mediated transfer of dominant-negative Rhokinase (DNRhoK) can effectively induce a regression of coronary arteriosclerotic lesions in our porcine model in vivo.
Methods
This experiment was reviewed by the Committee of the Ethics on Animal Experiments at Kyushu University and was carried out under the control of the Guidelines for Animal Experiments at Kyushu University.
Animal Preparation
Domestic male pigs (2 to 3 months old, weighing 25 to 30 kg) were sedated with intramuscular ketamine hydrochloride (1.5 mg/kg) and anesthetized with intravenous sodium pentobarbital (30 mg/kg). The animals were then intubated and ventilated with room air. Under aseptic conditions, the proximal segments of the left anterior descending and the left circumflex coronary arteries with a comparable external diameter were applied with a recombinant human IL-1␤ bead suspension (2.5 g in 0.05 mL) as described. 13 Two weeks after the operation, each animal was again anesthetized in the same manner, and then a 10F sheath was inserted through the carotid artery. After systemic heparinization (10 000 U per body), a preshaped 10F Judkins catheter was inserted into the carotid artery, and coronary angiography (CAG) in a left oblique view was performed. After the virus injection into the coronary artery wall, the carotid artery was ligated, the skin was closed, and the animal was allowed to recover from anesthesia. The animals were euthanized with an excess dose of intravenous pentobarbital (60 to 90 mg/kg), and coronary arteries were excised 1, 2, and 3 weeks after the procedure for immunostaining, organ chamber experiment and immunoblot analysis, and histological analysis, respectively.
Construction of Adenoviral Vectors
Rho-binding domain (RB) and mutant (NK 1036 3 TT) RB with a pleckstrin homology domain [RB/PH(TT)],which are DNRhoK mutants driven by the cytomegalovirus promoter with a c-myc tag, were prepared through homologous recombination between cotransfected pJM17 and the shuttle plasmids in 293 cells. Integration of the transgene into the adenoviral genome was determined by a polymerase chain reaction and restriction analysis. The titer of the virus stock was assessed by a plaque formation assay that used the 293 cell and was expressed as plaque-forming unit (pfu). AdLacZ was used as a control. 16 In the present study, AdDNRhoK represents an adenoviral vector encoding RB; however, we confirmed that an adenoviral vector encoding RB/PH(TT) also caused the same inhibitory effect on the constrictive vascular remodeling and vasospastic activity in the present porcine model in vivo (data not shown).
Adenovirus-Mediated Gene Transfer Into Porcine Coronary Arteries In Vivo
Two weeks after the application of IL-1␤, adenovirus-mediated gene transfer was performed at the coronary segments previously treated with the cytokine. The IL-1␤-treated coronary segment was easily recognized as a stenotic lesion by CAG after intracoronary administration of nitroglycerin (10 g/kg) and heparin (3000 U). Then, infiltrator angioplasty balloon catheter (IABC, Interventional Technologies Inc) was advanced to the IL-1␤-treated segment, followed by inflation of a 3.5-mm balloon at 2.0 atm for 30 seconds. This catheter has 21 small nipples in 3 lines located on the surface of the balloon connected to the drug delivery port, 17 which is filled with virus solution until droplets appear through the needles before use. This catheter is useful for the direct delivery of fluid into the vessel wall in vivo with Ͼ90% efficiency and minimal vascular damage 17 and also for in vivo gene transfer into the coronary artery. 16 AdLacZ and AdDNRhoK (final titer, 4ϫ10 9 pfu in 0.4 mL sorbitol-added lactated Ringer's saline) were injected into the coronary segment in a randomized manner, and then the catheter was deflated and withdrawn.
CAG and Coronary Diameter Measurement
CAG was performed before and every week until 3 weeks after the gene transfer. The cineangiograms were projected on a screen by using a cine projector, and an end-diastolic frame was selected and printed. Coronary stenosis at the IL-1␤-treated segments was expressed as the percent decrease in the luminal diameter compared with the mean diameter of adjacent proximal and distal normal coronary segments after intracoronary administration of nitroglycerin (10 g/kg). Coronary hyperconstrictions induced by intracoronary administration of serotonin (10 g/kg) and histamine (10 g/kg) were expressed as the percent decrease in luminal diameter from the control level, as previously described. 13 
Coronary Intravascular Ultrasound Imaging
To assess the extent of constrictive remodeling of the coronary artery in vivo, we performed intravascular ultrasound (IVUS) imaging immediately before and 3 weeks after the gene transfer. A 30-MHz 3.5F monorail ultrasound catheter interfaced with a monitor and scanner (HP SONOS, Hewlett-Packard) was used. After intracoronary administration of heparin (3000 U) and nitroglycerin (10 g/kg), the catheter was placed over the guidewire beyond the lesion site. The catheter was then withdrawn manually during continuous imaging recorded on a VHS videotape. The target lesion and a proximal reference site were selected for measurement. The target lesion was easily defined as the site with marked hyperechoic density in the adventitial area due to the chronic treatment with IL-1␤. The medial area at the IL-1␤-treated site was relatively hypoechoic compared with the adventitia. At each selected site, the intimal leading edge and the leading edge of the adventitia were used to manually trace the lumen and external elastic lamina (EEL) areas, respectively. Constrictive remodeling was assessed by calculating the percent reduction of the EEL and the luminal area at the IL-1␤-treated coronary segments to the EEL and the luminal area of the proximal normal coronary segments, respectively.
Immunostaining for c-Myc
Immunostaining for c-myc, a tag protein of DNRhoK, was performed 1 and 3 weeks after the gene transfer to confirm the efficacy of the procedure. After the coronary artery was excised, it was quickly frozen in OCT compound (Tissue-Tek), sectioned at 5 m, and subjected to immunostaining with polyclonal antibody against c-myc (Peninsula Laboratory). Intact arteries and nonimmune rabbit IgG were used as controls. Immunoreactive materials were visualized by use of a biotinylated anti-rabbit IgG antibody (Wako), peroxidaselabeled streptavidin, and diaminobenzidine.
Organ Chamber Experiment
To examine the coronary reactivity in vitro, we performed an organ chamber experiment 2 weeks after the gene transfer, as previously described. 12, 14, 18 Serotonin (0.1, 0.3, and 1.0 mol/L) induced contractions of the isolated coronary rings without endothelium, which rapidly developed and reached a maximum in 5 to 8 minutes. The developed tension was expressed as a percentage of that attained in the last precontraction with 62 mmol/L KCl.
Western Blot Analysis for Substrates of Rho-Kinase
Isolated coronary rings without endothelium and adventitial tissue were subjected to SDS-PAGE immunoblot analysis 2 weeks after the gene transfer. 12 Phosphorylation of the myosin-binding subunit (MBS) of myosin phosphatase was measured when the serotonin (1.0 mol/L)-induced contraction reached a maximum. Phosphorylation of ERM (ezrin/radixin/moesin) and of adducin was measured without serotonin. The antibodies used in the present study included rabbit anti-rat MBS polyclonal antibody (pAb), 19 rabbit anti-human moesin pAb (anti-phosphorylated Thr558), which also binds to the phosphorylated ezrin (Thr567) and radixin (Thr564), 20 and rabbit anti-human ␣-adducin pAb (anti-phosphorylated Thr445). 21 
Histological Examination
Three weeks after the gene transfer, the left coronary arteries were subjected to histological examinations. The medial area, percent medial area (ratio of medial area to EEL area), the neointimal area, and percent intimal area (ratio of intimal area to internal elastic lamina [IEL] area) were also calculated, and the degree of intimal and medial thickening was assessed. Constrictive remodeling of the coronary artery was assessed by measuring the ratio of the EEL, IEL, and luminal area at the IL-1␤-treated coronary segments to those respective areas of the adjacent proximal segments. 13 
Data Analysis
All results are expressed as the meanϮSEM. Multiple comparisons were made by ANOVA for repeated examinations followed by the Fisher post hoc test. Paired data were analyzed by the Student t test. A value of PϽ0.05 was considered to be statistically significant.
Results

Immunohistochemical Analysis for c-Myc
One week after the gene transfer, the expression of c-myc was noted throughout the media (smooth muscle cells) and partially at the adventitia (fibroblasts) at the AdDNRhoK-transfected site (online Figure I ; please see http://www.atvb.ahajournals.org). The staining with nonimmune IgG was negative, confirming the specificity of our immunostaining. Three weeks after the gene transfer, the immunoreactivity of c-myc was markedly reduced (data not shown). No immunoreactivity of c-myc was noted in the coronary segment adjacent to the AdDNRhoK-transfected site (data not shown).
CAG and Coronary Diameter Measurement
Coronary stenosis at the IL-1␤-treated site significantly regressed, and vasospastic response to serotonin (10 g/kg) Figure 1 . CAG in a pig before (top panels) and 2 weeks after (bottom panels) the transfer of AdDNRhoK (white arrowheads) or AdLacZ (black arrowheads) after intracoronary administration of 10 g/kg nitroglycerin (NG, left panels), 10 g/kg serotonin (middle panels), and 10 g/kg histamine (right panels). At the IL-1␤-treated site, coronary stenotic lesions and hyperconstrictive responses to serotonin and histamine, which were inhibited at the AdDNRhoK site but not at the AdLacZ site, were noted. and histamine (10 g/kg) progressively decreased at the AdDNRhoK site, whereas those changes persisted at the AdLacZ site (Figures 1 and 2 ).
Coronary IVUS
No significant difference in the extent of constrictive remodeling was noted between the AdDNRhoK and the AdLacZ site before the gene transfer (Figure 3 ). However, 3 weeks after the gene transfer, the constrictive remodeling induced by the IL-1␤ application markedly regressed at the AdDNRhoK site, whereas it persisted at the AdLacZ site (Figure 3 ).
Histological Examination
The EEL, IEL, and luminal areas were all significantly reduced by the IL-1␤ application, whereas this constrictive remodeling markedly regressed at the AdDNRhoK site but not at the AdLacZ site (online Figure II ; please see http:// www.atvb.ahajournals.org and Figure 4 ). Because the neointimal formation at the IL-1␤-treated site was minimal, the luminal reduction was caused primarily by the constrictive remodeling. There was no significant reduction in the media or the neointima at the AdDNRhoK site compared with the AdLacZ site, indicating that the enlargement of luminal area was caused primarily by the regression of constrictive remodeling but not by the reduction in the media or the neointima (Figure 4 ).
Organ Chamber Experiment
Serotonin (0.1, 0.3, and 1.0 mol/L) induced concentrationdependent contractions of isolated coronary rings without endothelium. The serotonin-induced contractions were augmented at the AdLacZ site compared with the normal site, whereas they were significantly suppressed at the AdDNRhoK site ( Figure 5 ). The extent of the hypercontractions at the AdLacZ site was comparable to that of coronary segments treated with IL-1␤ alone. 12, 14 
Measurement of Rho-Kinase Activity
Rho-kinase-dependent phosphorylation of MBS on stimulation by serotonin (1.0 mol/L) was increased at the AdLacZ site compared with the normal site, whereas it was suppressed at the AdDNRhoK site ( Figure 6A) . Furthermore, the phosphorylation of the ERM family and of adducin was also increased at the AdLacZ site and was markedly suppressed at the AdDNRhoK site ( Figure 6B ).
Discussion
The novel findings of the present study were that (1) Rhokinase and its substrates (ERM family and adducin) were functionally upregulated at the IL-1␤-treated arteriosclerotic coronary lesions in vivo, and (2) the selective inhibition of Rho-kinase by the gene transfer of its dominant-negative mutant caused a marked regression of the coronary constrictive remodeling and abolished the coronary vasospastic activity in vivo. To the best of our knowledge, this is the first report that demonstrates that selective inhibition of Rhokinase induces a regression of coronary arteriosclerotic lesions in vivo.
Rho-Kinase and Coronary Arteriosclerosis
We have recently demonstrated that Rho-kinase is upregulated at the IL-1␤-treated coronary lesions in our porcine model, causing coronary vasospastic responses through the inhibition of myosin phosphatase. 12 The present study further demonstrated that the Rho-kinase-mediated phosphorylation of ERM and of adducin 20, 21 is also increased at the coronary lesions, further confirming the upregulation of Rho-kinase. Recent studies in vitro have shown that Rho-kinase (and thus its substrates) mediates actin cytoskeleton organization, 7, 8 cell adhesion and migration, 9 and cytokinesis, 10 which may be regulated by adhesion complexes that consist of focal adhesion, anchoring proteins, and actin filament. 9 It has also been demonstrated that ERM and adducin are phosphorylated by Rho-kinase and are involved in cell adhesion and cell migration. 20 -22 We also have recently demonstrated that Rho-kinase is upregulated after balloon injury in porcine femoral arteries. 23 Among the cellular functions mediated by Rho-kinase and its substrates, cell adhesion may regulate 3D structure of blood vessels, including vascular remodeling, because it is a molecular basis of tissue architecture. 24 Although the molecular mechanism of the upregulation of Rho-kinase at the arteriosclerotic coronary lesions remains to be elucidated, it has recently been demonstrated that IL-1␤ directly enhances the Rho-kinase activity in vitro. 25 In our porcine model, a cytokine network is activated; this network involves platelet-derived growth factor, 13 fibroblast growth factor-2, 26 and inflammatory cytokines, 27 all of which could cause upregulation of Rho-kinase. Furthermore, accumulating evidence indicates that Rho-kinase is involved in the vascular effects of various vasoactive factors, including angiotensin II, 28 thrombin, 29 endothelin-1, 30 and serotonin. 12, 14 Thus, Rho-kinase may play an important role in the pathogenesis of arteriosclerosis directly (by enhancing the process through activation of its substrates) and indirectly (by mediating the signal transduction of various vasoactive mediators).
Rho-Kinase as a Novel Therapeutic Target in Treatment of Arteriosclerosis
One of the novel findings of the present study is that the selective and local inhibition of Rho-kinase, by the in vivo transfer of its dominant-negative mutant, induces a marked regression of the coronary constrictive remodeling in our porcine model. This result indicates that Rho-kinase is involved in the constrictive remodeling. It is now widely accepted that luminal narrowing after coronary angioplasty is caused primarily by constrictive remodeling, with a minimal contribution of neointimal formation. 31, 32 We have previously demonstrated that adventitial inflammatory/proliferative responses play an important role in the pathogenesis of the geometric remodeling in porcine coronary arteries in vivo, where adventitial delivery of antiproliferative agents (eg, tyrosine kinase inhibitors) is useful in preventing the process. 33 Because the structure of the arteriosclerotic artery is affected by cell adhesion, cytoskeleton organization, and smooth muscle cell contractility, Rho-kinase might be involved in the vascular remodeling. Recent studies have indicated that collagen accumulation and endothelial dysfunction are associated with constrictive remodeling. 34 Because endothelial vasodilator function is fairly preserved in our porcine model, 35 inflammatory vascular changes associated with collagen accumulation (especially at the adventitia) may play a primary role in the vascular remodeling.
We have also recently demonstrated that in vivo transfer of DNRhoK inhibits the neointimal formation after balloon injury in porcine femoral arteries in vivo. 23 In the present study, the inhibitory effect of DNRhoK on neointimal formation was not evident. This is probably because of the differences between the 2 models in terms of preexisting neointimal formation. In the present study, DNRhoK was transfected into the coronary artery with neointimal formation, whereas in the previous study, it was transfected immediately after balloon injury into the femoral artery without neointimal formation. It has been also reported that a Rho-kinase inhibitor exerts an inhibitory effect on the neointimal formation by balloon injury in rat carotid arteries. 36 Thus, Rho-kinase could be regarded as a novel therapeutic target in the treatment of arteriosclerosis.
Rho-Kinase as a Novel Therapeutic Target in Treatment of Vasospasm
Another novel finding of the present study was that the in vivo transfer of DNRhoK abolished the vasospastic activity of the coronary artery. We have previously demonstrated that acute administration of Rho-kinase inhibitors suppresses the coronary vasospastic responses in our porcine model. 12, 14 We confirmed that at 3 weeks after the transfer of DNRhoK, its immunoreactivity was markedly reduced in the coronary artery. Thus, the abolishment of the coronary vasospastic activity might mainly be due to the marked regression of the coronary remodeling (probably associated with the reduction in Rho-kinase expression, per se) and partly be due to the direct inhibitory effect of DNRhoK on the coronary contraction. This finding suggests the potential usefulness of Rhokinase inhibitors in the treatment of coronary artery spasm because they could abolish the coronary vasospastic activity. This potential effect of Rho-kinase inhibitors is in contrast to that of calcium channel blockers, which cannot abolish the vasospastic activity, per se, as evidenced by the rebound coronary spasm after abrupt cessation. 37 
Limitations of the Present Study
Several limitations of the present study could be raised. First, the present study was performed in a porcine model of coronary arteriosclerosis but not in humans. Thus, our observations should be confirmed in humans in a future study. Second, although the DNRhoK used in the present study potently inhibits Rho-kinase activity in vivo, it cannot be ruled out that other Rho and Rho-kinase effectors (eg, p140mDia, protein kinase N, and myosin light chain kinase) might also be involved in the inhibitory effect of DNRhoK. Third, the adenoviral vector may not be suitable for repeated gene transfer because of its intrinsic immunity. An inhibitory method of immunity and a less immunogenic vector remain to be developed for clinical use.
In summary, the present study has demonstrated that Rho-kinase is involved in the pathogenesis of constrictive remodeling and vasospastic responses of the coronary artery in our porcine model in vivo, suggesting that the molecule could be regarded as a novel therapeutic target in the treatment of arteriosclerotic vascular diseases.
